

OFFICIAL

MAY 22 2002

GROUP 1600

Sub
E1
cont.

O-sulpho- α -D-glucopyranoside or a salt thereof per kg body weight of the patient.

B1
cont.

12. (Amended) A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering by injection to the patient or to the circuit 0.30 to 30 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof.

B2
Sub
C2

15. (Amended) A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering by injection to the patient or to the circuit 0.001 to 10 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof per kg body weight of the patient.

16. (Amended) A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing